These Flu Season Stocks Are on Sale
Flu season is one of those unavoidable annual realities: it shows up, it spreads fast, and it sends a meaningful portion of the country looking for prevention, relief, and treatment, often all at once.
For consumers, that means flu shots, sanitizer, disinfecting wipes, cough-and-cold aisles, and pharmacy runs. For investors, it often means something else: a recurring seasonal tailwind for a handful of well-positioned, high-visibility names.
And this year, the public-health backdrop is already getting intense.
The CDC’s most recent surveillance update (Week 51, reflecting data through the week ending December 20, 2025) estimates at least 7.5 million flu illnesses, 81,000 hospitalizations, and 3,100 deaths so far this season, with eight pediatric deaths reported to date.
That’s not just noise. It’s a real-time reminder that the “flu season trade” is not theoretical in 2026, it’s happening.
The seasonal reality: flu is a recurring market catalystFlu season isn’t pleasant, but it is predictable. And from a market standpoint, predictable catalysts can create repeatable opportunities, especially when investor attention rotates toward safety, consumer staples, and healthcare access. Context matters here:
And now, for 2026, early-season numbers are already elevated, with the CDC recommending that everyone 6 months and older who hasn’t yet been vaccinated get an annual flu shot. When the data turns ugly, consumer behavior changes quickly:
That’s why flu season often becomes a quietly powerful catalyst for select stocks, particularly those that sit at the intersection of household staples + healthcare access. Two names stand out right now because they combine that seasonal tailwind with something investors love in uncertain tape: income. |
American Alternative Asset
Why insiders are whispering “$24,000 gold”
It's not a conspiracy theory. It's historical math.
If gold were revalued to back just 17% of the U.S. national debt — like it has in the past — it would need to be worth $24,000 an ounce.
That number didn't come from speculation. It comes from the same formula used during previous monetary resets.
And now Washington insiders, hedge fund billionaires, and even Trump himself are openly discussing moves that point to a gold reset.
You won't hear this on CNBC.
But if you wait for headlines, you'll already be too late.
That's why we created the free report, Trump's $24,000 Panic Button.
It reveals the signals insiders are acting on — and shows how everyday Americans can protect their retirement before this reset hits.
Company: Clorox (SYM: CLX) One of the simplest flu-season beneficiaries is also one of the most straightforward to own: Clorox. When illness is spreading, demand tends to rise for cleaning and disinfecting staples, exactly where Clorox has brand equity and shelf presence. This isn’t a “get rich quick” story. It’s a defensive positioning story with an embedded seasonal boost. Right now, the setup is especially notable for income-focused investors:
That yield matters. In a market where investors often “rent” momentum, a near-5% yield lets you get paid while you wait, especially if the stock is already washed out and the seasonal narrative is strengthening. The seasonal angleHistorically, CLX has often shown strength as flu season approaches and activity rises (frequently clustering around the fall-to-winter window). There have been multiple years where CLX moved higher during the flu-season build. This year, the additional ingredient is positioning: if shares are already depressed, it can take less incremental buying to move the stock. That’s exactly how “on sale” seasonal trades tend to work. Bad sentiment sets the table, and a recurring catalyst supplies the spark. What to watchCLX isn’t risk-free. If costs rise, volumes soften, or the market rotates aggressively out of staples, you can still see downside. But if you’re evaluating a flu-season basket, CLX offers a clear combination of:
Company: CVS Health (SYM: CVS) If Clorox captures the “home hygiene” spend, CVS captures the “health access” spend. Flu season creates more than just demand for OTC remedies, it drives vaccinations, prescriptions, rapid tests, and store traffic. CVS is one of the most direct public-market ways to get that exposure at scale. As of January 2, 2026, CVS is trading around $80. And CVS brings a meaningful income component as well:
Why CVS fits flu seasonEven without “perfect” seasonality, the business model lines up with how consumers behave when respiratory illness spikes:
And notably, the CDC’s surveillance update highlighted widespread activity and a sharp rise in illness counts as of late December 2025. The tactical viewThere's a historical tendency for CVS to show strength heading into flu season in multiple years. While no pattern is guaranteed, seasonality matters most when it aligns with fundamentals and sentiment. In CVS’s case, the market has also been focused on operational performance and outlook. Recent coverage has emphasized improved guidance and expectations for continued momentum into 2026, which can support the stock alongside any seasonal tailwind. Found this helpful? Share it with others. Written by Ian Cooper Our Flagship Publication Discover Great Companies Trading at a DiscountJoin Behind the Markets |